Evaluation of the Valiant Captivia Physician Fenestrated Stent Graft System in Aortic Arch and Descending Thoracic Aorta Pathologies
A legfontosabb adatok
- Ki végzi
- Ceric Sàrl
- Hol
- Franciaország4 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toboroz
- Résztvevők
- 30 fő, tervezett
- Kezdés
- 2023. nov. 21.
- Várható befejezés
- 2027. okt.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- The Valiant Captivia Stent Graft
- A regiszteradat frissítve
- 2024. május 1.
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 80 feltétel megnézéseKevesebb
Ki vehet részt
- TAA/PAU (Thoracic Aortic Aneurysms and Penetrating Ulcers):
- Subject is at least 18 years of age
- Subject understands and has signed an Informed Consent approved by the Sponsor for this study
- Subject must be considered a candidate for revascularisation of BT, LCCA and LSA
- Subject must be able to tolerate surgical revascularisation of BT, LCCA and LSA
- Subject has a TAA/PAU which is:; a fusiform aneurysm with a diameter of ≥ 5.5 cm OR is > 2 times the diameter of the non-aneurysmal thoracic aorta; AND/OR; a saccular aneurysm or PAU (ulcer defined as ≥ 10 mm in depth and 20 mm in diameter, or symptomatic)
- Subject has a healthy, non-diseased aortic proximal seal zone of at least 20 mm
- Subject has no thrombus in the proximal neck
- Subject has a non-diseased aortic diameter between 25 mm and 42 mm and max diameter of the ascending aorta is ≤ 40 mm
- Subject has a non-diseased LSA which is eligible for stent-grafting
- Subject has sufficient landing zone within the LSA to accommodate the stent-graft without occlusion of any significant vessels
- Brachial, iliac or femoral artery access vessel morphology (diameter, calcification, tortuosity) that is compatible with vascular access techniques, the device, or accessories
- Symptomatic patient who needs semi urgent repair; aptient is at high surgical risk and cannot wait for 6-8 weeks for a custom-made stent graft
- Subject is affiliated with the social security system
- TBAD(Type B Dissections) and Residual dissection after Type A repair:
- Subject is at least 18 years of age
- Subject understands and has signed an Informed Consent approved by the Sponsor for this study
- a) Subject has a degenerative aortic arch aneurysm which will require coverage of the LSA and extension of the proximal seal zone to zone 0 And/or b) Subject has a complicated TBAD (acute, subacute or chronic) which will require coverage of the LSA and extension of the proximal seal zone to zone 0 And/or c) Subject has a complicated residual dissection after replacement of the ascending aorta for type A aortic dissection which will require coverage of the LSA and extension of the proximal seal zone to zone 0
- Subject has a healthy, non-diseased (without thrombus) aortic proximal seal zone of at least 20 mm
- Subject has a healthy, non-diseased (without thrombus) aortic distal seal zone of at least 20 mm
- Subject has a maximum diameter of the distal ascending aorta just above the BT of 40 mm
- Subject has a non-diseased aortic diameter between 28 mm to 42 mm and the ascending aorta ≤ 40 m
- Subject has a no atheromatous lesions int the arch and the BT, LCCA and LSA
- Brachial, iliac or femoral artery access vessel morphology (diameter, calcification, tortuosity) that is compatible with vascular access techniques, the device, or accessories
- Symptomatic patient who needs semi urgent repair; aptient is at high surgical risk and cannot wait for 6-8 weeks for a custom-made stent graft
- Subject is affiliated with the social security system
Ki nem vehet részt
- Subject has circumferential calcification in the common femoral or external iliac artery or in the common iliac artery with an intraluminal diameter (ID) less than 9 mm at any point proximal to or at the access vessel site unless a surgical adjunctive procedure is planned
- Subject has had previous endovascular repair of the ascending
- Subject has coronary artery disease with unstable angina and who has not received treatment
- Subject is currently participating in an investigational drug or device clinical trial that would interfere with the observations of this study
- Subject has had previous surgical or endovascular treatment of an infra-renal aortic aneurysm <30 days of implantation of investigational device
- Subject has circumferential calcification in the common femoral artery, external iliac artery or in the common iliac artery with an intraluminal diameter (ID) less than 9 mm at any point proximal to or at the access vessel site unless a surgical adjunctive procedure is planned
- Subject has had previous endovascular repair of the ascending, arch
- Subject has coronary artery disease with unstable angina and who has not received treatment
- Subject is currently participating in an investigational drug or device clinical trial that would interfere with the observationsof this study
- Subject has had previous surgical or endovascular treatment of an infra-renal aortic aneurysm <30 days of implantation of investigational device
- Subject has prohibitive calcification, occlusive disease, or tortuosity of intended sealing sites
- Subject has a known allergy or intolerance to the device components
- Subject is in acute renal failure
- Subject has a connective tissue disease (e.g. Marfan's syndrome, medial degeneration)
- Subject has active systemic infection and/or a mycotic aneurysm
- Subject has a history of bleeding diathesis, coagulopathy, or refuses blood transfusion
- Subject has had a myocardial infarction (MI) within 3 months
- Subject has a known hypersensitivity or contraindication to anticoagulants or contrast media, which is not amenable to pre-treatment
- Subject has prohibitive calcification, occlusive disease, or tortuosity of intended sealing sites
- Subject has a known allergy or intolerance to the device components
- Subject is in acute renal failure
- Subject has a connective tissue disease (e.g. Marfan's syndrome, medial degeneration)
- Subject has active systemic infection and/or a mycotic aneurysm
- Subject has a history of bleeding diathesis, coagulopathy, or refuses blood transfusion
- Subject has had a myocardial infarction (MI) within 3 months
- Subject has a known hypersensitivity or contraindication to anticoagulants or contrast media, which is not amenable to pre-treatment; -
- (Thoracic Aortic Aneurysms and Penetrating Ulcers, TAA/PAU):
- Subject has an aneurysmal, tortuous, or atherosclerotic LSA
- Subject has an aneurysmal, tortuous, or atherosclerotic LCCA
- Subject has an aneurysmal, tortuous, or atherosclerotic BT
- Subject has an ascending aorta diameter > 40 mm
- Subject has thrombus in the proximal neck
- Subject has an emergent need of treatment of the aortic pathology
- Subject has an aortic atheroma classified as grade IV or grade V
- Subject has significant and/or circumferential aortic mural thrombus at either the proximal or distal attachment sites that would compromise sealing of the device
- Subject is pregnant
- Subject has a body habitus which prevents adequate visualisation of the aorta
- Subject has other medical, social, or psychological problems that, in the opinion of the investigator, will interfere with treatment and follow-up procedures
- Subject has a life expectancy of less than 2 years year
- Subject requires treatment of an infrarenal aneurysm at the time of the implantation
- Subject has had a cerebral vascular accident (CVA) within 3 months
- (Type B Dissections, TBAD and residual dissection after Type A repair):
- Subject has an aneurysmal, tortuous, or atherosclerotic LCCA
- Subject has an aneurysmal, tortuous, or atherosclerotic LSA
- Subject has an aneurysmal, tortuous, or atherosclerotic BT
- Subject has a dissected BT and or LCCA
- Subject has an aortic atheroma classified as grade IV or grade V
- Subject has significant and/or circumferential aortic mural thrombus at either the proximal or distal sealing sites that would compromise seal of the device
- Subject is pregnant
- Subject has a body habitus which prevents adequate visualisation of the aorta
- Subject has other medical, social, or psychological problems that, in the opinion of the investigator, will interfere with treatment and follow-up procedures
- Subject has a life expectancy of less than 2 years
- Subject requires treatment of an infrarenal aneurysm at the time of the implantation
- Subject has had a cerebral vascular accident (CVA) within 3 months
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
The study objectives are to assess safety and effectiveness, measured acutely and at the 30-day visit after implantation of the Valiant Captivia physician fenestrated Stent Graft.
A teljes eredeti leírásKevesebb
Clinical utility measures throughout the procedure and until discharge will be assessed
A vizsgálat csoportja
- Intervention/TreatmentA vizsgált kezelés
The Valiant Captivia physician fenestrated stent graft for the treatment of aneurysms/penetrating ulcers, Type B aortic dissections or residual dissection after Type A repair, of the aortic arch and the descending thoracic aorta which are candidates for revascularisation of all three supra-aortic vessels (BT, LCCA, LSA)
Kezelés: The Valiant Captivia Stent Graft
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- A regiszteradat frissítve
- 2024. május 1.